Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen

Tissue Antigens

Volumn 48, Issue 4 I, 1996, Pages 242-254

  Hayden, M S ^a   Grosmaire, L S ^a   Norris, N A ^a   Gilliland, L K ^a   Winberg, G ^a   Tritschler, D ^a   Tsu, T T ^a   Linsley, P S ^a   Mittler, R S ^a   Senter, P D ^a   Fell, H P ^a   Ledbetter, J A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antibody derivatives; CD28 sFv; Costimulation; Immunotherapy; Targeting costimulation

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; RECOMBINANT PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BINDING; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANIMALIA;

EID: 10344229501     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1996.tb02642.x     Document Type: Article

References (53)

1. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994: 179: 523-532.
2. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993: 259: 368-370.
3. Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992: 71: 1093-1102.
4. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994: 179: 1205-1214.
5. Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995: 182: 1415-1421.
6. Johnston JV, Malacko AR, Mizuno MT et al. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J Exp Med 1996: 183: 791-800.
7. Hodge JW, AAbrams S, Schlom J, Kantor JA. Induction of anti-tumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994: 54: 5552-5554.
8. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol 1995: 155: 5498-5505.
9. McHugh RS, Ahmed SN, Wang Y-C, Sell KW, Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A 1995: 92: 8059-8063.
10. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S. Rejection of MHC class II transfected tumor cells requires induction of tumor encoded B7-1 and/ or B7-2 costimulatory molecules. J Immunol 1996: 156: 3821-3827.
11. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991: 174: 561-569.
12. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994: 1: 405-413.
13. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4-receptors. Immunity 1994: 1: 793-801.
14. Kariv I, Truneh A, Sweet RW. Analysis of the site of interaction of CD28 with its counter-receptors CD80 and CD86 and correlation with function. J Immunol 1996: 157: 29-38.
15. Peach RJ, Bajorath J, Brady W et al. Complementarity determining region 1 (CDR1)-and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1996: 180: 2049-2052.
16. Hayden MS, Linsley PS, Gayle MG et al. Single-chain mono-and bispecific antibody derivatives with novel biological properties and anti-tumor activity from a COS cell transient expression system. Ther Immunol 1994: 1: 3-15.
17. Gilliland LK, Norris NA, Marquardt H et al. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments. Tissue Antigens 1996: 47: 1-20.
18. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidmium thiocyhanade phenol-choroform extraction. Anal Biochem 1987: 162: 156-159.
19. Marken JS, Schieven GL, Hellstrom KE, Hellstrom I, Aruffo A. Cloning and expression of the tumor associated antigen L6. Proc Natl Acad Sci U S A 1992: 89: 3503-3507.
20. Fell HP, Gayle MA, Yelton D et al. Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. J Biol Chem 1992: 267: 15552-15558.
21. Barsoum J. Introduction of stable high-copy-number DNA into chinese hamster ovary cells by electroporation. DNA Cell Biol 1990: 9: 293-300.
22. Urlaub G, Mitchell PJ, Kas E et al. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat Cell Mol Genet 1986: 12: 555-566.
23. Jung G, Ledbetter JA, Muller-Eberhard HJ. Induction of cytotoxicity in resting human T lymphocyhtes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sci U S A 1987: 84: 4611-4615.
24. Olio R, Auffray C, Morchamps C, Rougeon F. Comparison of mouse immunoglobulin gamma2a and gamma2b chain genes suggests that exons can be exchanged between genes in a multigenic family. Proc Natl Acad Sci U S A 1981: 78: 2442-2446.
25. Altenburger W, Neumaier P, Steinmetz M, Zachau HG. DNA sequence of the constant gene region of the mouse immunoglobulin kappa chain. Nucleic Acids Res 1981: 9: 971-981.
26. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996: 271: 1734-1736.
27. Umlauf SW, Beverly B, Kang SM, Brorson K, Tran AC, Schwartz RH. Molecular regulation of the IL-2 gene: rheostatic control of the immune system, Immunol Rev 1993: 133: 177-197.
28. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A 1993: 90: 5687-5690.
29. Levitsky HI, Montgomery J, Ahmadzadeh M et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996: 156: 3858-3865.
30. Dranoff G, Jeffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti tumor immunity. Proc Natl Acad Sci U S A 1993: 90: 3539-3542.
31. Renner C, Jung W, Sahin U et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994: 264: 833-835.
32. Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983: 305: 537-540.
33. Staerz UD, Bevan MJ. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci U S A 1986: 83: 1453-1457.
34. Liu MA, Kranz DM, Kurnick JT, Boyle LA, Levy R, Eisen HN. Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1985: 82: 8648-8652.
35. Lanzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 1981: 17: 105-111.
36. Gilliland LK, Clark MR, Waldmann H. Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells. Proc Natl Acad Sci U S A 1988: 85: 7719-7723.
37. Traunecker A, Lanzavecchia A, Karjalainen K. Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J 1991: 10: 3655-3659.
38. Winter G, Milstein C. Man-made antibodies. Nature 1991: 349: 293-299.
39. Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 1995: 92: 7021-7025.
40. Queen C, Schneider WP, Selick HE et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989: 86: 10029-10033.
41. Yelton DE, Rosok MJ, Cruz G et al. Affinity maturation of the BF96 anti-carcinoma antibody by codon-based mutagenesis. J Immunol 1995: 155: 1994-2004.
42. Jeffrey PD, Bajorath J, Chang CY et al. The x-ray structure of an anti-tumor antibody in complex with antigen. Nat Struct Biol 1995: 2: 466-436.
43. Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ. Potent inhibition of human immunodeficiency virus type 1 replication by an intracelluar anti-Rev single chain antibody. Proc Natl Acad Sci U S A 1994: 91: 5075-5079.
44. Marasco WA, Haseltine WA, Chen SY. Design, intracellular expression, and acitivity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A 1993: 90: 7889-7893.
45. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A 1996: 93: 2702-2707.
46. Fell HP, Gayle MA, Grosmaire L, Ledbetter JA. Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab′) with specificity for carcinomas and human IL2. J Immunol 1991: 146: 2446-2452.
47. Francisco JA, Gilliland LK, Stebbins MR, Morris NA, Ledbetter JA, Siegall CB. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res 1995: 55: 3099-3104.
48. Ducancel F, Gillet D, Carrier A, Lajeunesse E, Menez A, Boulain JC. Recombinant colorimetric antibodies: construction and characterization of a bifunctional F(ab) 2/alkaline phosphatase conjugate produced in Escherichia coli. Biotechnology 1993: 11: 601-605.
49. Gruber M, Schodin BA, Wilson ER, Kranz DM. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol 1994: 152: 5368-5374.
50. Yang J, Moyana T, Xiang J. A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor. Mol Immunol 1995: 32: 873-881.
51. ras J Exp Med 1994: 180: 1067-1076.
52. Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellstrom KE. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res 1986: 46: 3917-3923.
53. DeNardo SJ, Warhoe KA, O'Grady LF et al. Radioimmunotherapy for breast cancer: treatment of a patient with I-131 L6 chimeric monoclonal antibody. Int J Biol Markers 1991: 6: 221-230.